Seelos Announces Issuance of a New Patent and an Additional Notice of Allowance in Japan for Intranasal Racemic Ketamine (SLS-002)
PR85570
NEW YORK, Sept. 14, 2020 /PRNewswire=KYODO JBN/ --
- Patents Further Strengthen Global Intellectual Property Portfolio in
Psychiatry
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical
company focused on the development of therapies for central nervous system
disorders and rare diseases, announced today that it has received an issued
patent from the Japanese Patent Office (Japanese patent number 6722453)
covering SLS-002 titled: ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF
USE. The issued claims cover a formulation and method of using SLS-002 to
treat patients experiencing anxiety due to phobic disorders such as: Specific
Phobia, Agoraphobia, and Social Phobia.
Logo – https://mma.prnewswire.com/media/1244961/Seelos_Therapeutics_Logo.jpg
Additionally, Seelos has received a Notice of Allowance from the Japanese
Patent Office (Japanese patent application number 2018-124196) covering SLS-002
titled: ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE. The allowed
claims cover a formulation and method of using SLS-002 to prevent anxiety in
patients prior to medical or dental procedures.
Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
www.seelostherapeutics.com
https://www.linkedin.com/company/seelos
SOURCE Seelos Therapeutics, Inc.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
